Sign in
Taking people in PolandPhase 2

Tests naxitamab in people with Ewing's sarcoma that has not responded to treatment

Tests naxitamab added to chemotherapy in people with hard-to-treat Ewing's sarcoma.

Key facts

Who runs it
Instytut Matki I Dziecka
Where
Warsaw and Wroclaw, PolandSee the 2 sites
Registry title
To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.
Status
Recruiting
Phase
Phase 2
People taking part
24 people, planned
Started
28 Sept 2023
Expected to end
30 Apr 2028
Type of study
Interventional
Record updated
6 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with Ewing sarcoma that has come back or kept growing after treatment, and whose tumour carries GD2.

Age
From 2 years to 21 years.
Sex
Both sexes can join.
Disease stage
Ewing sarcoma of the bone or soft tissues, proven by tissue examination. The disease has grown during or after at least one line of treatment, or has come back.
Earlier treatment
Earlier drug treatment for cancer must have ended at least 3 weeks before, major surgery at least 2 weeks before, and radiation at least 4 weeks before. Earlier treatment with an anti-GD2 antibody is not allowed.
Biomarker or test result
The tumour must be GD2 positive (tested by IHC). A stored tumour sample must be available to test GD2.

Main reasons for not taking part

  • Another cancer diagnosed before joining the trial
  • Needing steroids above 10 mg prednisolone (or equivalent) a day, or other drugs that weaken the immune system
  • Pregnancy, breastfeeding or planning to become pregnant during treatment
  • Serious heart or lung problems
  • Allergy to the study drugs

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Histologically proven Ewing sarcoma of the bone or soft tissues
  • Consent to the use of effective contraception throughout the period of the study and a minimum of 1 year after discontinuation of study treatment in patients at puberty and sexual maturity
  • Subject's archival tumour sample (formalin-fixed, paraffinembedded; FFPE) available for evaluation of GD2 expression
  • Documented disease progression (during or after completion of at least one line treatment) or any subsequent recurrence
  • GD2 positive tumor assessed by IHC
  • Age ≥ 2 years and ≤ 21 years
  • Life expectancy of at least 12 weeks from the time informed consent was signed
  • Previous systemic anticancer treatment completed ≥ 3 weeks, major surgery ≥ 2 weeks, and radiation therapy ≥ 4 weeks prior to study enrollment
  • Recovered from adverse effects of prior surgery, radiotherapy, or anti-neoplastic therapy at the discretion of the investigator
  • Signing of informed consent for trial participation (including for naxitamab treatment) according with current legal regulations

Who cannot take part

  • Requirement, or likely requirement, for corticosteroids at doses >10 mg prednisolone (or equivalent) per day or other immunosuppressive agents
  • Planning to become pregnant (while being treated with IT or naxitamab), pregnancy or breastfeeding
  • Previous treatment with an anti-GD2 antibody
  • Simultaneous treatment with other drugs which might interact with naxitamab or IT regimen
  • Persistent toxicity related to prior therapy, making it impossible to treat with naxitamab
  • Failure to meet any of the inclusion criteria
  • Diagnosis of other malignancies before study inclusion
  • Hypersensitivity to the study drugs or any of their ingredients (covers IT and naxitamab)
  • Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial
  • Significant cardiac conduction abnormalities, including known familial prolonged QT syndrome, or screening QTc >480 msec
  • Symptoms of congestive heart failure or left ventricular ejection fraction <50%
  • Not eligible to IT
  • Inadequate pulmonary function defined as evidence of dyspnea at rest, exercise intolerance, and/or chronic oxygen requirement. In addition, room air pulse oximetry < 94% and/or abnormal pulmonary function tests if these assessments are clinically indicated

Where in Poland

  • Instytut Matki i DzieckaWarsaw, PolandTaking people
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandTaking people

About the trial

What the trial wants to find out

Safety assessment of the addition of naxitamab to standard 3-week chemotherapy (CHT) in patients with refractory Ewing's sarcoma (ES)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.
Plain-language title
Tests naxitamab in people with Ewing's sarcoma that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 August 2024